Compugen (CGEN) Expected to Announce Quarterly Earnings on Monday

Compugen (NASDAQ:CGEN) is projected to announce its Q1 2026 results before the market opens on Monday, May 18th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $1.5720 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 18, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. The business had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Stock Performance

NASDAQ:CGEN opened at $2.90 on Monday. The stock’s 50-day simple moving average is $2.38 and its 200 day simple moving average is $1.94. The company has a market cap of $274.20 million, a P/E ratio of 7.84 and a beta of 2.79. Compugen has a 52-week low of $1.26 and a 52-week high of $3.23.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CGEN. Franklin Resources Inc. bought a new position in shares of Compugen during the 2nd quarter worth approximately $56,000. Jane Street Group LLC boosted its stake in shares of Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after acquiring an additional 359,785 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Two Sigma Investments LP boosted its stake in shares of Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the period. Finally, Raymond James Financial Inc. boosted its stake in shares of Compugen by 51.0% during the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 34,215 shares during the period. 12.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on CGEN shares. Lake Street Capital started coverage on Compugen in a research report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. Truist Financial raised Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. Finally, Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.